Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | RARB | P10826 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12224519 | 0.95 | L3MBTL1 (0.56) | L3MBTL1FFAR1FFAR4PLA2G4BKDM4E | |
| SCHEMBL12224513 | 0.95 | L3MBTL1 (0.56) | L3MBTL1FFAR1FFAR4PLA2G4BKDM4E | |
| SCHEMBL1822418 | 0.86 | L3MBTL1 (0.67) | L3MBTL1FFAR1FFAR4MEN1KMT2A | |
| SCHEMBL1822003 | 0.84 | FFAR1 (0.58) | L3MBTL1FFAR1FFAR4PLA2G4BMEN1 | |
| SCHEMBL17732030 | 0.83 | KDM4E (0.52) | L3MBTL1FFAR1FFAR4KDM4EMEN1 | |
| SCHEMBL19489958 | 0.81 | PPARA (0.61) | L3MBTL1FFAR1FFAR4PLA2G4BKDM4E | |
| SCHEMBL8355954 | 0.81 | PPARA (0.61) | L3MBTL1FFAR1FFAR4PLA2G4BKDM4E | |
| SCHEMBL28543148 | 0.81 | PPARA (0.61) | L3MBTL1FFAR1FFAR4PLA2G4BKDM4E | |
| SCHEMBL12223524 | 0.81 | PKM (0.56) | L3MBTL1FFAR1PPARA | |
| SCHEMBL5638782 | 0.81 | PKM (0.56) | L3MBTL1FFAR1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180074067-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN GROUP LIMITED (GB) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180074067-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | L3MBTL1 3469/4885FFAR1 3921/4885FFAR4 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.